# US 2021/0275516 A1 · Lactate enhancing compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275516 A1
- Document ID: US20210275516A1
- Status: Published application
- Kind: A1
- Application number: 17/257,333
- Filed: 2019-07-01
- Published: 2021-09-09
- Earliest claimed: 2018-07-02
- Assignees: Ecole Polytechnique Federale De Lausanne (Epfl); Gliapharm SA
- Applicants: Ecole Polytechnique Federale De Lausanne (Epfl); Gliapharm SA
- Inventors: PIERRE MAGISTRETTI; SYLVAIN LENGACHER; CHARLES FINSTERWALD
- Web page: https://patentgrep.com/patent/US20210275516A1

## CPC

- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- C07D 217/22: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 217/02: with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new agents useful for stimulating release of lactate by astrocytes. The invention further relates to methods of preparation, formulations and therapeutic uses of those agents, notably for the prevention and/or treatment of neurological disorders, in particular neurodegenerative and psychiatric disorders or improving cognitive and memory functions.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A method of preventing or treating a disorder or a disease associated with an abnormally low intracerebral energy metabolism or in the central nervous system and/or a neurodegenerative disorder in a subject, said method comprising administering in a subject in need thereof a therapeutically effective amount of a compound of Formula (I),
wherein R1, R2, R3, R4, R5 and R6 are independently selected from H, halogen, optionally substituted alkoxy, optionally substituted C1-C6 alkyl, optionally substituted amine, optionally substituted carboxylic acid or ester, nitro and nitrile; R7, R8, R9, R10 and R11 independently selected from H, halogen, optionally substituted alkoxy, optionally substituted C1-C6 alkyl, optionally substituted amine, optionally substituted carboxylic acid or ester, nitro and nitrile and a group of Formula (II): —(X)m—CR12R13R14 (II) wherein at least one group of R7, R8, R9, R10 and R11 is a group of Formula (II); X is selected from O, NR15, S, CH2 and hydrazine (—N—N—), m is an integer elected from 0 and 1 and R12, R13 and R14 are independently selected from H, OH, optionally substituted alkoxy, optionally substituted C1-C6 alkyl and halogen, wherein at least one of R12, R13 and R14 is F or Cl; Y is selected from —CR16R17— and —NR18—; R15 is selected from H, optionally substituted alkoxy and optionally substituted C1-C6 alkyl; R16 and R17 are independently selected from H, halogen, optionally substituted alkoxy, optionally substituted C1-C6 alkyl and optionally substituted aryl; R18 is independently selected from H or optionally substituted C1-C6 alkyl; or pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms, enantiomeric mixtures thereof, and mixtures thereof.

### Claim 23 (depends on 22)

The method according to claim 22, wherein X is selected from O, NR15, S or hydrazine (—N—N—).

### Claim 24 (depends on 22)

The method according to claim 22, wherein Y is —NR18.

### Claim 25 (depends on 22)

The method according to claim 22, wherein Y is —CR16R17.

### Claim 26 (depends on 22)

The method according to claim 22, wherein R1, R4, R5 and R6 are H.

### Claim 27 (depends on 22)

The method according to claim 22, wherein R2 and R3 are selected from H, methoxy, or optionally substituted alkoxy.

### Claim 28 (depends on 22)

The method according to claim 22, wherein m is 1.

### Claim 29 (depends on 22)

The method according to claim 22, wherein R9 is a —(X)m—CR12R13R14 group.

### Claim 30 (depends on 22)

The method according to claim 22, wherein X is O.

### Claim 31 (depends on 22)

The method according to claim 22, wherein R12, R13 and R14 are F.

### Claim 32 (depends on 22)

The method according to claim 22, wherein R7, R8, R10 and R11 are H.

### Claim 33 (depends on 22)

The method according to claim 22, wherein R9 is OCF3 or CF3.

### Claim 34 (depends on 22)

The method according to claim 22, wherein said disorder or a disease is selected from amyotrophic lateral sclerosis, dementia, Alzheimer's disease, frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease, multiple sclerosis, stroke, traumatic brain injury, a psychotic disorder, depression, schizophrenia, mild cognitive impairments or epilepsy.

### Claim 35 (depends on 22)

The method according to claim 22, wherein said compound is selected from:
6,7-dimethoxy-N-(4-(trifluoromethoxy)phenyl)isoquinolin-1-amine;
6,7-dimethoxy-N-(4-(trifluoromethyl)phenyl)isoquinolin-1-amine;
N-(4-(trifluoromethoxy)phenyl)isoquinolin-1-amine; or
6,7-dimethoxy-1-(4-(trifluoromethoxy)benzyl)isoquinoline;
or a tautomer, geometrical isomer, optically active form, enantiomeric mixture, pharmaceutically acceptable salt or mixture thereof.

### Claim 36

A pharmaceutical composition comprising a compound of Formula (I)
wherein R1, R2, R3, R4, R5 and R6 are independently selected from H, halogen, optionally substituted alkoxy, C1-C6 alkyl, optionally substituted by halogen C1-C6 alkoxy, amino, nitro, optionally substituted amine, optionally substituted carboxylic acid or ester, nitro and nitrile; R7, R1, R9, R10 and R11 independently selected from H, halogen, optionally substituted alkoxy, optionally substituted C1-C6 alkyl, optionally substituted amine, optionally substituted carboxylic acid or ester, nitro and nitrile and a group of Formula (II): —(X)m—CR12R13R14 (II) wherein at least one group of R7, R8, R9, R10 and R11 is a group of Formula (II); X is selected from O, NR15, S, CH2 and hydrazine (—N—N—), m is an integer elected from 0 and 1 and R12, R13 and R14 are independently selected from H, OH, optionally substituted alkoxy, optionally substituted C1-C6 alkyl and halogen, wherein at least one of R12, R13 and R14 is F or Cl; Y is selected from —CR16R17— and —NR18—; R15 is selected from H, optionally substituted alkoxy and optionally substituted C1-C6 alkyl; R16 and R17 are independently selected from H, halogen, optionally substituted alkoxy, optionally substituted C1-C6 alkyl and optionally substituted aryl; R18 is independently selected from H or optionally substituted C1-C6 alkyl; and pharmaceutically acceptable salts, hydrates, solvates, or polymorphs, tautomers, geometrical isomers, optically active forms, enantiomeric mixtures thereof, and mixtures thereof, and a pharmaceutically acceptable carrier, diluent or excipient thereof, with the proviso that it is not a compound selected from:
N-[2-(trifluoromethyl)phenyl]isoquinolin-1-amine;
N-[3-(trifluoromethyl)phenyl]isoquinolin-1-amine; and
N-[4-(trifluoromethyl)phenyl]isoquinolin-1-amine.

### Claim 37

A compound selected from:
6,7-dimethoxy-N-(4-(trifluoromethoxy)phenyl)isoquinolin-1-amine;
6,7-dimethoxy-N-(4-(trifluoromethyl)phenyl)isoquinolin-1-amine;
N-(4-(trifluoromethoxy)phenyl)isoquinolin-1-amine; or
6,7-dimethoxy-1-(4-(trifluoromethoxy)benzyl)isoquinoline;
or a tautomer, geometrical isomer, optically active form, enantiomeric mixture, pharmaceutically acceptable salt or mixture thereof.

### Claim 38 (depends on 37)

A pharmaceutical composition comprising at least one compound according to claim 37 and a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 39 (depends on 38)

The pharmaceutical composition according to claim 38 further comprising at least one co-agent useful for treating and/or stabilizing a neurodegenerative disorder or abnormally low intracerebral energy metabolism or enhancing cognitive and memory functions.

### Claim 40 (depends on 36)

A method of increasing the intracerebral lactate levels in a subject, said method comprising administering in a subject in need thereof an effective amount of a composition according to claim 36.

### Claim 41 (depends on 36)

A method for enhancing cognitive and memory functions in a subject, said method comprising administering an effective amount of a composition according to claim 36.
